1. Home
  2. ATEC vs IRON Comparison

ATEC vs IRON Comparison

Compare ATEC & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alphatec Holdings Inc.

ATEC

Alphatec Holdings Inc.

HOLD

Current Price

$19.88

Market Cap

3.2B

Sector

Health Care

ML Signal

HOLD

Logo Disc Medicine Inc.

IRON

Disc Medicine Inc.

HOLD

Current Price

$90.97

Market Cap

3.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATEC
IRON
Founded
1990
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2B
3.4B
IPO Year
2006
N/A

Fundamental Metrics

Financial Performance
Metric
ATEC
IRON
Price
$19.88
$90.97
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
12
Target Price
$22.00
$108.83
AVG Volume (30 Days)
2.1M
560.9K
Earning Date
10-30-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$728,020,000.00
N/A
Revenue This Year
$26.83
N/A
Revenue Next Year
$16.61
N/A
P/E Ratio
N/A
N/A
Revenue Growth
27.11
N/A
52 Week Low
$8.70
$30.82
52 Week High
$22.66
$99.50

Technical Indicators

Market Signals
Indicator
ATEC
IRON
Relative Strength Index (RSI) 47.95 53.38
Support Level $19.77 $90.40
Resistance Level $21.42 $94.51
Average True Range (ATR) 0.68 3.70
MACD -0.36 -0.60
Stochastic Oscillator 5.54 32.55

Price Performance

Historical Comparison
ATEC
IRON

About ATEC Alphatec Holdings Inc.

Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others.

About IRON Disc Medicine Inc.

Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.

Share on Social Networks: